A brain can­cer ef­fort more than a decade in the mak­ing has cul­mi­nat­ed in a dis­ap­point­ing study re­sult — but re­searchers be­hind it are con­tend­ing...

Chen Yu's TCGX, a pri­vate and pub­lic biotech in­vest­ment firm, is go­ing to in­vest di­rect­ly in life sci­ences com­pa­nies in Chi­na and else­where in Asia...

Cari­bou Bio­sciences is reach­ing the end of the road.

The Cal­i­for­nia biotech said Tues­day it is shelv­ing two al­lo­gene­ic CAR-T cell ther­a­py pro­grams and seek­ing...

Match­point Ther­a­peu­tics, a biotech part­nered with No­var­tis, has put to­geth­er its lat­est fi­nanc­ing round.

The $150 mil­lion Se­ries B will help fundMatch­point’s ef­forts to...

For years, sci­en­tists as­sumed that cells in the brain be­gan de­cay­ing im­me­di­ate­ly af­ter death. But re­searchers threw ice on that the­o­ry sev­en years ago when...